Aug 04, 2022 8:12am EDT DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
Aug 01, 2022 4:32pm EDT DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022
Jul 06, 2022 4:41pm EDT DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
May 25, 2022 4:15pm EDT DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022
May 04, 2022 4:32pm EDT DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results
Apr 28, 2022 8:15am EDT DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022
Mar 14, 2022 4:45pm EDT DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results
Mar 08, 2022 8:13am EST DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022
Feb 02, 2022 8:43am EST DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer
Jan 25, 2022 8:43am EST DiaMedica Therapeutics to Present Research at International Stroke Conference